Results 1-59 of 59 (Search time: 0.004 seconds).

Issue DateTitleAuthor(s)SourcescopusWOSFulltext/Archive link
12021The Short- and Long-term Causal Relationships Between Self-compassion, Trait Mindfulness, Caregiver Stress, and Depressive Symptoms in Family Caregivers of Patients with Lung CancerHsieh C.-C.; ZHONG-ZHE LIN ; Ho C.-C.; Yu C.-J.; Chen H.-J.; Chen Y.-W.; Hsiao F.-H.Mindfulness0
22021Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinomaChen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN ; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F.Diagnostics0
32020A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib MonotherapyZHONG-ZHE LIN ; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.Oncologist2
42020Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancerYang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN ; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H.Clinical and Translational Radiation Oncology2
52020Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in lifeHsieh C.-C.; Ho C.-C.; ZHONG-ZHE LIN ; Yu C.-J.; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; Hsiao F.-H.Psychology and Health2
62019First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinomaKim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.Cancer Discovery62
72019Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinomaShao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN ; Cheng A.-L.; Hsu C.-H.Liver International15
82019Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinomaZHONG-ZHE LIN ; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L.Liver International12
92019Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutationsLin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN ; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.International Journal of Cancer24
102019A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinomaQin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN ; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.Therapeutic Advances in Medical Oncology24
112019Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patientsYao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN ; Lin C.-C.; Yang J.C.-H.; Yu C.-J.European Journal of Cancer13
122019Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation statusChen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN ; Yang M.-C.PLoS ONE1
132019Considerations of heterogeneity in clinical trials for hepatocellular carcinomaLiu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN ; Hsu C.-H.; Cheng A.-L.Expert Review of Gastroenterology and Hepatology5
142017Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN ; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.Cancer Chemotherapy and Pharmacology14
152017Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinibYao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN ; Lin C.-C.; Yang J.C.H.; Yu C.-J.Oncologist19
162017Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacyShao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN ; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.Alimentary Pharmacology and Therapeutics6
172016Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort studyChen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN ; Lai M.-S.; Cheng A.-L.; Yeh K.-H.BMC Cancer31
182015The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseasesChiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; ZHONG-ZHE LIN ; Lan K.-H.; Cheng A.-L.; Kuo S.-H.PLoS ONE9
192015Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinomaLiao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.Clinical Lung Cancer7
202015The prognostic impact of type 2 diabetes mellitus on early cervical cancer in AsiaKuo H.-Y.; ZHONG-ZHE LIN ; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.Oncologist9
212015Young patients with colorectal cancer have increased risk of second primary cancersLiang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; ZHONG-ZHE LIN ; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.Japanese Journal of Clinical Oncology7
222015Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in TaiwanShao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN ; Cheng A.-L.; Lai M.-S.Clinical Colorectal Cancer25
232014Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancerShen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.Oncology (Switzerland)10
242014Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancerChen K.-H.; Shao Y.-Y.; ZHONG-ZHE LIN ; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S.Oncologist16
252014Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinomaOu D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN ; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.Journal of Gastroenterology and Hepatology (Australia)12
262014Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruptionZHONG-ZHE LIN ; Chou C.-H.; Cheng A.-L.; Liu W.-L.; Chia-Hsien Cheng J.International Journal of Cancer13
272013A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapyShao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN Liver International12
282013Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinomaLu L.-C.; Shao Y.-Y.; Kuo R.N.C.; ZHONG-ZHE LIN ; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.Cancer9
292013Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor sizeZHONG-ZHE LIN ; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.PLoS ONE22
302013Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancerShao Y.-Y.; Shau W.-Y.; ZHONG-ZHE LIN ; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S.European Journal of Cancer18
312013The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiformeLee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN ; Cheng A.-L.; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.Oncology (Switzerland)8
322012Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapyZHONG-ZHE LIN ; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.Oncologist10
332012Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based studyZHONG-ZHE LIN ; Shau W.-Y.; Shao Y.-Y.; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S.Oncologist6
342012Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinomaShau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.Oncologist31
352012Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systemsShao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN ; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.British Journal of Cancer24
362012Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinomaShao Y.-Y.; ZHONG-ZHE LIN ; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.Oncology25
372012The impact of diabetes mellitus on prognosis of early breast cancer in AsiaChen W.-W.; Shao Y.-Y.; Shau W.-Y.; ZHONG-ZHE LIN ; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S.Oncologist34
382012Survival of patients with small cell lung carcinoma in TaiwanKuo Y.-H.; ZHONG-ZHE LIN ; Yang Y.-Y.; Shao Y.-Y.; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S.Oncology15
392012A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumorYang S.-H.; Lin C.-C.; ZHONG-ZHE LIN ; Tseng Y.-L.; Hong R.-L.Investigational New Drugs24
402011High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapyShao Y.-Y.; ZHONG-ZHE LIN ; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.Oncology15
412011Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinomaShao Y.U.-Y.; Chen P.-J.; ZHONG-ZHE LIN ; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.Anticancer Research
422010Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinomaHsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN ; Chao T.-Y.; Cheng A.-L.British Journal of Cancer107
432010Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinomaShao Y.-Y.; ZHONG-ZHE LIN ; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.Cancer129
442010Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCCZHONG-ZHE LIN ; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; Lee P.; Cheng A.-L.; Hsu H.-C.BMC Cancer76
452010Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsLin C.-C.; Hsu H.-H.; Sun C.-T.; Shih J.-Y.; ZHONG-ZHE LIN ; Yu C.-J.; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; Yang C.-H.; Mok T.Journal of Thoracic Oncology22
462010Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaHsu C.-H.; Shen Y.-C.; ZHONG-ZHE LIN ; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.Journal of Hepatology101
472010Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinomaShao Y.; Huang C.; Liang P.; ZHONG-ZHE LIN Asia-Pacific Journal of Clinical Oncology25
482009The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinomaZHONG-ZHE LIN ; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.Journal of Hepatology38
492009A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomitingHo C.-L.; Su W.-C.; Hsieh R.-K.; ZHONG-ZHE LIN ; Chao T.-Y.Japanese Journal of Clinical Oncology14
502009Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survivalShen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN ; Chang M.-C.; Hsu C.; Cheng A.-L.Cancer Epidemiology Biomarkers and Prevention19
512009EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatmentHuang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; ZHONG-ZHE LIN ; Yu C.-J.; Cheng A.-L.; Yang P.-C.Lung Cancer34
522009Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphomaYang S.-H.; ZHONG-ZHE LIN ; Kuo S.-H.; Cheng A.-L.American Journal of Hematology1
532009Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatmentShao Y.-Y.; ZHONG-ZHE LIN ; Liang P.-C.; Tien Y.-W.; Cheng A.-L.Anticancer Research1
542009Sunitinib-induced myxedema comaChen S.-Y.; Kao P.-C.; ZHONG-ZHE LIN ; Chiang W.-C.; Fang C.-C.American Journal of Emergency Medicine0
552008High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapyPerng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y.Lung Cancer26
562008Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapyYang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; ZHONG-ZHE LIN ; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C.Journal of Clinical Oncology217
572008Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatmentZHONG-ZHE LIN ; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.Lung Cancer1
582007Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinomaLu Y.-S.; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; ZHONG-ZHE LIN ; Chen T.-J.; Cheng A.-L.; Chen C.-S.Hepatology77
592002Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphomaHuang C.-L.; ZHONG-ZHE LIN ; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L.Leukemia and Lymphoma5